drugset / Trial / NCT07146906
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
Timeline
- Start
- 2026-03-26
- Primary completion
- 2030-07-12
- Completion
- 2030-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zigakibart | Monoclonal antibody | 600 mg | Subcutaneous |